摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-(3-chloro-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one | 1005403-14-4

中文名称
——
中文别名
——
英文名称
8-(3-chloro-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one
英文别名
8-(3-chloropropoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one
8-(3-chloro-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one化学式
CAS
1005403-14-4
化学式
C15H15ClN2O2
mdl
——
分子量
290.749
InChiKey
RRTCENNFDOLRLX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    (R)-2-methylpyrrolidine benzenesulfonic acid salt8-(3-chloro-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-onepotassium carbonate 、 potassium iodide 作用下, 以 乙腈 为溶剂, 反应 14.0h, 生成 8-[3-((R)-2-methyl-pyrrolidin-1-yl)-propoxy]-5,6-dihydro-2H-benzo[h]cinnolin-3-one
    参考文献:
    名称:
    Pyridizinone derivatives
    摘要:
    本发明提供了式(I*)的化合物:它们作为H3抑制剂的用途,其制备方法以及药物组合物。
    公开号:
    US20080027041A1
  • 作为产物:
    参考文献:
    名称:
    Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists
    摘要:
    A novel class of benzocinnolinones analogs of irdabisant were designed and synthesized as histamine H3R antagonists/inverse agonists. Modifications to the pyridazinone portion of the core and linker led to the identification of molecules with excellent target potency and selectivity with improved rat pharmacokinetic properties and reduced potential hERG liabilities. (C) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2012.04.001
点击查看最新优质反应信息

文献信息

  • Pyridazinone Derivatives
    申请人:Bacon Edward R.
    公开号:US20110288075A1
    公开(公告)日:2011-11-24
    The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
    本发明涉及新型吡啶并咪唑酮衍生物,可介导酶活性。特别是,这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性,包括神经退行性疾病、睡眠/清醒障碍、注意力缺陷多动障碍和认知/认知障碍等。
  • TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS
    申请人:Brown Pamela
    公开号:US20100087424A1
    公开(公告)日:2010-04-08
    Tricyclic nitrogen containing compounds and their use as antibacterials.
    三环氮含有化合物及其作为抗菌剂的用途。
  • PYRIDAZINONE DERIVATIVES
    申请人:Bacon Edward R.
    公开号:US20140142088A1
    公开(公告)日:2014-05-22
    The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition.
    本发明涉及新型吡啶酮衍生物,可介导酶活性。特别地,这些化合物可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面具有有效性,包括但不限于神经退行性疾病、睡眠/觉醒障碍、注意力缺陷多动障碍和认知方面。
  • Aryl pyridazinone derivatives and their use as H3 receptor ligands
    申请人:Bacon Edward R.
    公开号:US08586588B2
    公开(公告)日:2013-11-19
    The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds and/or their pharmaceutically acceptable salts may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive disorders.
    本发明涉及新型吡啶并咪唑酮衍生物,可介导酶活性。特别是,这些化合物及/或其药学上可接受的盐可能在治疗与组胺H3受体活性相关的疾病或疾病状态方面有效,包括神经退行性疾病、睡眠/觉醒障碍、注意力缺陷多动症和认知/认知障碍等。
  • Pyridizinone Derivatives
    申请人:Cephalon, Inc.
    公开号:EP2492263A1
    公开(公告)日:2012-08-29
    The present invention provides compounds of formula (I*): their use as H3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.
    本发明提供了式 (I*) 的化合物: 它们作为 H3 抑制剂的用途、制备工艺及其药物组合物。
查看更多